Mikhail Blagosklonny enjoys a wide international reputation as a prominent scholar and scientist into the theories of anti-aging drugs. He acquired a Ph.D. in Cardiology and Experimental Medicine from the First Pavlov State Medical University of St. Petersburg. Among several other achievements he has made in the medical field is the honor he was given as a senior scientist at the prestigious Ordway Research Institute. He also obtained an MD from the same institution where he got the Ph.D. He was made an associate professor of medicine at the New York Medical College in Valhalla in 2002. However, in 2009 he proceeded to the Roswell Park Cancer Institute where he became the professor in the field of Oncology.
The science of aging is a subject that has caused a lot of controversies, and up to now, the scientists do not agree whether the natural process of aging can be reversed or stopped. A lot of time and money has been spent to try and find out a drug that can slow down the aging process; however what researchers have so far discovered is that the degradation of the body’s cells and tissues naturally lead to aging. They have yet to agree on how to stop the process altogether. One of the prominent scientists working to resolve the issue is Mikhail Blagosklonny who is a professor of Oncology at the Roswell Park Cancer Institute.
So far he has carried out extensive studies on the subject, and some of the notable areas his findings have touched include cellular and molecular biology in signal transductions, protection of special cells through a selection of drug resistance, anticancer therapeutics, mitosis, cell cycle, the suppression of tumor, and on ontogenesis. He is also renowned for authoring several high-level publications and research papers in cell psychotherapy, chemotherapeutic engineering, and the hyperfunction theory of aging. However, the subjected for which he is most famous is the study of oncology. He has over 300 research articles, several thousand book chapters, and reviews which are credited to his name. Apart from the numerous achievements, Mikhail Blagosklonny is also the associate editor for PLOS ONE, the American Journal of Pathology, and the International Journal of Cancer.
He is considered to be the leading authority on the science of aging because of the skills he has accumulated in the various places where he has worked. He devotes most of his time and studies in specialties such as the management of cancer, anti- aging drugs, and the protection of healthy cells through different cancer therapies so that they cannot be damaged further. The mechanisms that underlie the process of getting old or Biogerontology also take part a huge part of his interests. His most significant initiatives are the invention of Rapamycin for cancer management. Dr. Mikhail came up with TOR which demonstrates the potential for cancer and aging drugs. In the search for longevity, he advocates the use of Rapamycin, but above all the achievements, he is the editor-in-chief of Oncotarget and the Cell Cycle. Read more about Mikhail at LinkedIn.com